Healthcare >> Analyst Interviews >> January 26, 2004
DAVID MARTIN is the senior biotechnology analyst at Dundee Securities in
Toronto, Canada. Prior to joining Dundee, he was involved in biotech
research and investment banking at another Canadian firm, and has also
worked for a Big Four accounting firm and a European pharmaceutical
company. He earned an MBA from the Richard Ivey School of Business and a
PhD from the University of Western Ontario, based on work conducted at
the London Cancer Center, the Ontario Cancer Institute and the
University of Kentucky. His research took him to Italy, where he worked
on a year-long scholarship at a cancer institute near Milan. Profile
Securities? Are there certain areas of biotech that you focus on?
Mr. Martin: Actually, because the Canadian biotech sector
